Kyverna Therapeutics, Inc.
Kyverna Therapeutics (Nasdaq: KYTX) is a clinical-stage biopharmaceutical company developing cell therapies for autoimmune diseases. Its lead candidate, mivocabtagene autoleucel (miv-cel, also known as KYV-101), is an autologous, fully human CD19-targeting CAR T-cell therapy designed to deplete B cells. Kyverna is… From the company’s description.
In fiscal 2025, Kyverna Therapeutics, Inc. reported a net loss of $161.31M. Operations used $153.71M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Kyverna Therapeutics, Inc. does
In the company’s own words
Kyverna Therapeutics (Nasdaq: KYTX) is a clinical-stage biopharmaceutical company developing cell therapies for autoimmune diseases. Its lead candidate, mivocabtagene autoleucel (miv-cel, also known as KYV-101), is an autologous, fully human CD19-targeting CAR T-cell therapy designed to deplete B cells. Kyverna is advancing miv-cel in stiff person syndrome (SPS) and generalized myasthenia gravis (gMG), with additional studies exploring progressive multiple sclerosis, rheumatoid arthritis, lupus nephritis and systemic sclerosis. The company reported positive results from its registrational Phase 2 SPS trial and is preparing a biologics license application; its gMG program includes a Phase 3 trial. Kyverna also develops manufacturing and next-generation CAR T-cell technologies, including KYV-102, a rapid manufacturing process. The company focuses on research and development and reports no business segments in the available business description. Its website is https://www.kyvernatx.com/
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- EMERYVILLE, CA
- Fiscal year end
- December
- CIK
- 1994702
- SIC
- 2836
Financial performance, year by year
Fiscal 2024–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Kyverna Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Kyverna Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Kyverna Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Kyverna Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Kyverna Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”